Terence Williams, MD, PhDThe James Cancer Center
- Radiation Oncology
- Esophageal Cancers
- Pancreatic Cancers
- Gastrointestinal Cancers
- Liver Cancers
- Radiation Oncology
- Lung Cancers
- Colorectal Cancers
- Colon Cancers
- Rectal Cancers
- Stomach Cancers
- Anal Gland Cancer
- Carcinoma, Non-Small-Cell Lung
- Radiotherapy, Intensity-Modulated
- Small Cell Lung Carcinoma
Make an Appointment
I am a radiation oncologist who specializes on treating patients with thoracic and gastrointestinal cancers (with a particular emphasis on non-small cell lung cancer, pancreatic cancer, and hepatobiliary malignancies). I work with world-class colleagues in various disciplines such as surgical oncology and medical oncology to provide the best possible care for our patients.
My clinical interests include adapting novel radiotherapy techniques (such as stereotactic body radiotherapy) to improve outcomes for our patients, and utilizing functional imaging such as MRI and PET-CT to better understand how tumors respond to therapy. I am actively involved in bringing novel clinical trials to the Ohio State University, as well as developing our own clinical trials that will both provide the most innovative treatments for our patients. I serve key roles on multiple National Cancer Institute groups to develop trials incorporating new drug and radiation combinations.
Additionally, I head a research lab investigating new ways to treat cancer. My lab is funded to conduct research in DNA damage response mechanisms in normal and tumor cells after radiation or chemotherapy, particularly as it relates to oncogene activity. Oncogenes are proteins in tumor cells that are mutated and drive tumor growth and resistance to treatments. In addition, my research team and I attempt to better understand how tumors bring in nutrients into tumors cells and how these pathways may be exploited for therapeutic efficacy. Finally, we are actively involving in profiling tumors at the molecular level to identify new pathways that are aberrant and may be driving treatment resistance, as well as developing new molecular “signatures” that could predict outcomes or response to therapies.
I’ve received funding and awards from the National Cancer Institute, the National Institute of Health, the American Society of Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), American Cancer Society (ACS), and the Radiologic Society of North America (RSNA). I have given talks both at national and international conferences and universities regarding my research. We have also published numerous articles in medical journals including Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Molecular Cancer Therapeutics, and the Journal of Clinical Investigation.
Education and Background
Albert Einstein College of Medicine
University of Michigan Medical Center
Ann Arbor, MI
- American Board of Radiology (Subspecialty: Radiation Oncology)
- Department of Radiation Oncology
I see patients at
The James Cancer Hospital and Solove Research Institute
460 West 10th Avenue, Columbus, Ohio 43210
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 3/28/2017, Dr. Williams has reported financial relationships with the medical device, research and/or drug companies listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office at 614-293-7802.
- Covidien PLC